<DOC>
	<DOCNO>NCT00659789</DOCNO>
	<brief_summary>Current management HIV infection include anti-retroviral therapy ( ART ) . ART cure infection , make life-long treatment require sustain patient compliance imposes significant individual societal financial burden healthcare service . Furthermore , ART side effect often require medication increase inconvenience financial burden HIV management . Of concern emergence virus resistant ART result treatment failure . ART-free period could provide substantial benefit . Vacc-4x peptide-based HIV immunotherapy propose prolongation ART-free period . The purpose study determine whether Vacc-4x immunotherapy give safe ART-free period .</brief_summary>
	<brief_title>Immunogenicity Study Vacc-4x Versus Placebo Patients Infected With HIV</brief_title>
	<detailed_description>Current management HIV infection include anti-retroviral therapy ( ART ) . ART cure infection , make life-long treatment require sustain patient compliance imposes significant individual societal financial burden healthcare service . Furthermore , ART side effect often require medication increase inconvenience financial burden HIV management . Of concern emergence virus resistant ART result treatment failure . ART-free period could provide substantial benefit . Vacc-4x peptide-based HIV immunotherapy propose prolongation ART-free period . The purpose study determine whether Vacc-4x immunotherapy give safe ART-free period .</detailed_description>
	<criteria>Age 1855 HIV positive least one year Clinically stable ART least six month Documented viral load le 50 copies/mL last six month Documented prestudy CD4 cell count equal 400x10exp6/L Nadir CD4 cell count equal 200x10exp6/L Signed inform consent Reported prestudy AIDSdefining illness within previous year Malignant disease On chronic treatment immunosuppressive therapy Unacceptable value hematology clinical chemistry parameter Current chronic infection HCV HBV active tuberculosis Pregnant breastfeed woman Not use safe contraceptive method Participation clinical trial Incapability compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>